Aurigene has been established as a wholly-owned subsidiary of Dr. Reddy’s through the merger of Aurigene Discovery Services and Dr. Reddy’s Custom Pharma Services (CPS). The launch of the brand happened during the pandemic, and it is therefore the first opportunity for the team to exhibit the new brand to its customers.

Jayachandran Ezhuthachan, Head of BD North America at Aurigene, said: “We are a dynamic CDMO partner for global pharma companies. With our integrated offering, from clinical research to commercial manufacturing for small and large molecules, we can significantly speed up the journey of an NCE/NBE (New Chemical and Biological Entities) to the patient. Our team is very excited to join CPhI North America to meet with potential partners and discuss how we can support them. One of our relatively newer service offerings is the discovery and development services for New Biological Entities (NBEs). We establish and adopt innovative technology platforms for faster, reliable, and cost-effective solutions to complex problems throughout the pharmaceutical value chain. We understand customers’ needs across the product lifecycle and are equipped to provide them with phase appropriate solutions at every stage of the product development. We operate small-scale non-GMP to multi-tonne cGMP facilities to offer fast turnaround times from early phase supplies to commercial quantities. Our global regulatory expertise, quality standards, and ESG focus, and cost-effective operations, position us well to be a partner of choice for varied customer needs from big pharma, large CDMOs, or smaller biotech.

One of the recent recognitions of Aurigene Pharmaceutical Services, which underlines the commitment towards ESG, was for its efforts in Health, Safety, and the Environment (SHE): the CII-SR Excellence Silver Award 2021. 

Make sure to meet the Aurigene team at booth: # 1606

About Aurigene:

Aurigene Pharmaceutical Services Limited (APSL) is an integrated partner for global pharma companies. It covers the entire value chain for new therapeutics, from drug discovery, clinical research, and development to manufacturing APIs and formulation at commercial scales. It has development laboratories from discovery to clinical phase III for New Chemical and Biological Entities (NCEs/NBEs) and cGMP manufacturing facilities in the UK, Mexico, USA, and India.

…………………………………………………………………………